50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to maintain and restore sight in patients by building the leading vertically integrated retinal gene therapy company.”In use 2017 – now·1 sighting·SEC Form 424B4, filed 2017-09-2890% match
“Our mission is to develop disease-modifying, regenerative therapies to restore vision to millions of patients.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-01-2475% match
“Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated, leading biopharmaceutical company.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-2073% match
“Our mission is to improve the vision health and quality of life of patients around the world by developing medicines that save sight and improve eye care for patients.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-1172% match
“Our mission is to develop and commercialize novel therapeutics to treat diseases of the eye, with an initial focus on diseases of the back of the eye.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-2172% match
“Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2671% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2871% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1571% match
“Our mission is to develop, manufacture and distribute worldwide visual implants and other ophthalmic products that improve the vision of patients with cataracts, refractive conditions and glaucoma.”In use 2005 – now·1 sighting·SEC Form 10-K/A, filed 2005-04-2170% match
“Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0470% match
“Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2670% match
“Our mission is to build a world-class biopharmaceutical and biotechnology company, with a leading position in key therapeutic areas.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1270% match
“Our mission is to build a major ophthalmic pharmaceutical company.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-02-2770% match
“Our mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pathway.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2369% match
“Our mission is to build an ophthalmology-focused biopharmaceutical company that capitalizes on the gaps that we believe increasingly exist in the ophthalmology sector between single product companies and large, multi-product pharmaceutical companies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0669% match
“Our mission is to bring new medicines to patients suffering from blinding diseases, and we think you can play a key role in helping make our vision a reality.”In use 2014 – now·1 sighting·SEC Form S-1, filed 2014-06-3069% match
“Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-05-0169% match
“Our mission is to improve lives through the curative potential of gene therapy.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0168% match
“Our mission is to bring innovative gene therapy products to patients living with serious, life-threatening rare diseases, and we believe our product candidates have the potential to provide long-lasting and transformative benefits to the patient communities we aim to serve.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0168% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1868% match
“Our mission is to develop next generation cell and gene therapeutics with the capacity to cure.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0768% match
“Our mission is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2567% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1267% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0167% match
“Our mission is to become a leading fully-integrated pharmaceutical company delivering new medicines to patients with unmet medical needs.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-2867% match
“The Company’s mission is to improve lives through product innovation, research and development and outstanding patient and consumer experience.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1367% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2467% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1367% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0767% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2467% match
“Our mission is to create medicines that make a difference for patients, build value for our fellow stockholders, and empower our passionate team.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-02-2266% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0966% match
“Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.”In use 2011 – now·1 sighting·SEC Form S-1, filed 2011-02-0166% match
“Our mission is to advance to market novel regenerative medicine and cellular therapy products that substantially benefit humankind.”In use 2016 – now·1 sighting·SEC Form S-1/A, filed 2016-02-0266% match
“Our mission is to build an oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0366% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1966% match
“Our purpose is to innovate to bring therapies to patients that significantly improve their lives.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1366% match
“Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-1266% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2866% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2866% match
“Our mission is to significantly improve the treatment of vascular disease through the introduction of products based on our Lumivascular platform, the only intravascular real-time high-definition image-guided system available in this market.”In use 2024 – now·1 sighting·SEC Form 424B4, filed 2024-06-1766% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1166% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2466% match
“Our mission is to solve unmet medical needs by commercializing discoveries from research universities and medical centers We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient solutions.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-04-1165% match
“Our mission is to become a global leader in providing innovative, clinically proven solutions to treat patients suffering from OSA.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-2665% match
“Our mission is to reimagine therapeutics and their delivery.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-0165% match
“Our mission is to use our technology to create a new generation of RNAi therapeutics which can improve outcomes for patients.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-09-0865% match
“Our mission is to improve the lives of patients by accelerating the development of our customers’ drugs and devices through innovative solutions.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-2765% match
Showing 1–50 of 50